A team of experts led by IBEC research associate Jordi Alacaraz have discovered how lung adenocarcinoma recruits cancer-associated fibroblasts, and the impact this phenomenon has on the spread of the tumour and the generation of metastases. The results have shown that these cells have a migratory advantage in early stages of the tumour. In the research, they also tested the inhibitor drug Trametinib, which proved to be suitable for eliminating this early migratory movement.
You can read the news at:
